These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3148668)

  • 1. Pharmacokinetics of recombinant murine interferon-gamma in mice.
    Rutenfranz I; Kirchner H
    J Interferon Res; 1988 Oct; 8(5):573-80. PubMed ID: 3148668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of liposome-encapsulated human interferon-gamma after intravenous and intramuscular injection in mice.
    Rutenfranz I; Bauer A; Kirchner H
    J Interferon Res; 1990 Jun; 10(3):337-41. PubMed ID: 2117038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration.
    Ferraiolo BL; Fuller GB; Burnett B; Chan E
    J Biol Response Mod; 1988 Apr; 7(2):115-22. PubMed ID: 3129541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of recombinant murine interferon-gamma and human interferon-alpha A/D(Bgl) administered in concert and their influence on natural killer cell function in mice.
    Chen SA; Shalaby MR; Crase DR; Palladino MA; Baughman RA
    J Interferon Res; 1988 Oct; 8(5):597-608. PubMed ID: 3148670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution of recombinant mouse interferon-gamma and recombinant human interferon-gamma in mice, rats, hamsters, and monkeys.
    Nishiuchi M; Kai K; Izawa M; Sato K; Yamada H
    J Interferon Res; 1991 Oct; 11(5):267-9. PubMed ID: 1774465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inability of recombinant interferon-gamma to activate the antibacterial activity of mouse peritoneal macrophages against Listeria monocytogenes and Salmonella typhimurium.
    van Dissel JT; Stikkelbroeck JJ; Michel BC; van den Barselaar MT; Leijh PC; van Furth R
    J Immunol; 1987 Sep; 139(5):1673-8. PubMed ID: 2957433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the co-promoting activity of gamma interferon in SENCAR and C57BL/6 mouse skin by difluoromethylornithine and the scheduling and duration of interferon treatment.
    Reiners JJ; Pavone A; Rupp T; Cantu AR
    Carcinogenesis; 1990 Jan; 11(1):129-37. PubMed ID: 2104781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo.
    Hockertz S; Franke G; Kniep E; Lohmann-Matthes ML
    J Interferon Res; 1989 Oct; 9(5):591-602. PubMed ID: 2507661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.
    Kurzrock R; Rosenblum MG; Sherwin SA; Rios A; Talpaz M; Quesada JR; Gutterman JU
    Cancer Res; 1985 Jun; 45(6):2866-72. PubMed ID: 3921249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
    Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
    J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.
    Celada A; Gray PW; Rinderknecht E; Schreiber RD
    J Exp Med; 1984 Jul; 160(1):55-74. PubMed ID: 6330272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
    Iigo M; Nishikata K; Nakajima Y; Moriyama M
    Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of an endogenous tumor necrosis factor in mice by murine recombinant interferon-gamma combined with a lipid A subunit analog (GLA-60) of low toxicity.
    Saiki I; Maeda H; Sakurai T; Murata J; Iida J; Kiso M; Hasegawa A; Azuma I
    Cancer Immunol Immunother; 1989; 29(2):101-8. PubMed ID: 2497979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog.
    Gibson DM; Cotler S; Spiegel HE; Colburn WA
    J Interferon Res; 1985; 5(3):403-8. PubMed ID: 4056487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the antitumor effect of two types of murine recombinant interferons, (beta) and (gamma), against B16-F10 melanoma.
    Sakurai M; Iigo M; Tamura T; Otsu A; Sasaki Y; Nakano H; Nakagawa K; Minato K; Ohe Y; Saijo N
    Cancer Immunol Immunother; 1988; 26(2):109-13. PubMed ID: 3129191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes.
    Cantell K; Hirvonen S; Pyhälä L; De Reus A; Schellekens H
    J Gen Virol; 1983 Aug; 64 (Pt 8)():1823-6. PubMed ID: 6409993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
    Silagi S; Dutkowski R; Schaefer A
    Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal circadian timing reduces the myelosuppressive activity of recombinant murine interferon-gamma administered to mice.
    Koren S; Fleischmann WR
    J Interferon Res; 1993 Jun; 13(3):187-95. PubMed ID: 8366285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic study of partially pure gamma-interferon in cancer patients.
    Gutterman JU; Rosenblum MG; Rios A; Fritsche HA; Quesada JR
    Cancer Res; 1984 Sep; 44(9):4164-71. PubMed ID: 6430557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.
    Itoh T; Sakata Y; Yoshida Y; Tsushima K; Suzuki H; Saitoh S; Tamura Y; Ogasawara H; Sugimoto N; Takemori H
    Cancer Immunol Immunother; 1990; 32(2):88-94. PubMed ID: 2126986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.